Studying of Interleikin-2 Immunomodular Effect under Critical Conditions

Nino Kajaia

Department of Anesthesiology, Critical Care and Catastrophe Medicine, Tbilisi State Medical University, Georgia;
Critical Care Medical Institute, Tbilisi, Georgia

The results showed, that using of Interleikin-2 did not change immunity statistically (P>0,05), before and after treatment, but after using it, the results of immunodeficiency were not increased. Patient of that group did not receive the above-mentioned preparation and the treatment was done by traditional methods. On the next stage of critical condition, immuno-depression was increased. We must take into consideration the fact that in the group of patients who were not cured by Interleukin was noted signs in 48%, but in the group of patients, who took that treatment there was only 18%. The mortality in Interleukin treated group was 42% and in non-Interleikin cured group the Mortality was 60%. The conclusion was made; that Interleikin-2 may be used during critical situation for prevention therapy in critical conditions, together with basic therapy.

Keywords:  critical conditions, immunomodular, interleikin-2